TARGETING DRUG TO HIV SANCTUARY IN LYMPHATIC

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 淋巴结被认为提供了持续存在于接受高效抗逆转录病毒治疗的患者体内的蓄水池。当停止药物治疗时，持续的病毒可以繁殖，导致病毒迅速回到普通循环中，并经常出现耐药突变。我们的目标是利用靶向给药来增加抗HIV药物在淋巴结和淋巴组织中的浓度，从而减少或消除这些病毒库。药物将通过掺入脂质体或脂质纳米颗粒进行靶向治疗，众所周知，这些纳米颗粒会排出并积聚在淋巴结中。利用氟代脱氧葡萄糖(F18-FDG)和正电子发射断层扫描(PET)来识别淋巴组织中的代谢活性，其基础是由于HIV复制活跃而导致的葡萄糖代谢增加。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The lymph nodes are thought to provided reservoirs where persists in patients undergoing highly active antiretroviral therapy. When drug therapy is discontinued, the persistent virus can multiply, leading to a rapid return of virus to the general circulation and frequently, the emergence of drug resistant mutants. Our objective is to use targeted drug delivery to increase the concentration of anti-HIV drugs in the lymph nodes and lymphoid tissues thus diminishing or elimination these viral reservoirs. Drugs will be targeted by incorporate into liposome or lipid nano-particles, which are known to drain and accumulate in the lymph nodes. Using fluorine deoxyglucose (F18-FDG) and positron emission tomography (PET) is to identify metabolic activity in lymphoid tissues based on increase glucose metabolism due to active HIV replication.